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David R. Holmes, JR, MD, Douglas L. Packer, MDA s is widely appreciated by all medical andsurgical specialties, atrial ﬁbrillation is themost common signiﬁcant cardiac arrhythmia
seen in practice; approximately 5 to 7 million pa-
tients in the United States have atrial ﬁbrillation,
with the numbers expected to increase to approxi-
mately 16 million by 2050 (1), and there are 200,000
to 250,000 new cases each year. Although symptoms
vary widely, the most concerning one relates to
thromboembolism with stroke and/or transient
ischemic attack.
For many patients, as well as for individuals
without known medical problems, stroke is the most
feared medical catastrophe. From a societal stand-
point, strokes are also extremely concerning. Direct
annual stroke-related medical costs are predicted
to increase dramatically from $72 billion to $183
billion between 2012 and 2030 (2). In addition, many
survivors of stroke remain signiﬁcantly limited. In the
setting of atrial ﬁbrillation, the risk of stroke has
been well studied and is increased by approximately
5-fold. The relationship between increasing age,
increasing incidence of atrial ﬁbrillation, and
increasing incidence of stroke has also been well*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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St. Jude Medical for mapping technology.studied (3–5). A variety of stroke risk scores have been
developed to identify those at highest risk of stroke.
The most common currently used is the CHADS2-
VASc score (6). Such scores are used increasingly for
patient education and decision making, and form an
important part of professional guidelines. Such scores
are particularly useful in identifying patients at very
low risk of stroke as well as those at the other end of
the spectrum.
In the past, anticoagulation with vitamin K antag-
onists (VKA) or novel factor Xa or direct thrombin
inhibitors have been found to be effective for stroke
prevention, reducing its incidence by approx-
imately two-thirds, and have become the new stan-
dard of care (7). However, although very effective, a
substantial number of patients at risk for stroke are
not treated because of increased risk of bleeding,
previous bleeding episodes, patient frailty, inability
to consistently follow medication recommendations,
drug–drug interactions, patient discontinuation of
drugs during follow-up, and managing physician
uncertainties as to the required treatment for their
patients (8). In the highest-risk patients, including
elderly patients, a substantial number, and in some
practices even a majority of the elderly patients, are
not treated.SEE PAGE 1915This, plus the information that, in the setting
of nonvalvular atrial ﬁbrillation, thromboembolic
events typically arise from the left atrial appendage,
has led to the development of local, directed site-
speciﬁc therapy for stroke prevention with a variety
of surgical and catheter-based techniques. Such local
site-speciﬁc therapy could prevent left atrial
appendage thromboembolic events without the need
for long-term anticoagulant agents. Closing the oval
door (or the left atrial appendage oriﬁce, which is
actually oval in most patients) is the approach studied
in the paper by Dr. Wiebe et al. (9) in this issue of
JACC: Cardiovascular Interventions. It is focused on
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1923the only U.S. Food and Drug Administration–
approved device for stroke prevention in the setting
of nonvalvular atrial ﬁbrillation, namely the
Watchman device, and adds signiﬁcant information
to the published data. This device has been well
described and has been the focus of 2 completed
randomized clinical trials, 2 post-market approval
registries and multiple meta-analyses (10–12). This
current speciﬁc paper includes a single-center expe-
rience with a relatively large number of patients
(N¼ 102) whowere at high stroke risk but also had high
bleeding risk with a mean CHA2DS2-VASc score of 4.3
 1.7 and HAS-BLED score of 2.9  1.2, respectively.
In this group, treated at a very experienced center,
procedural success was excellent (96.1%). Procedure-
related complications occurred in 8.8% of the entire
group, typically the result of a pericardial effusion.
There was some trend toward a learning curve, with
11.8% complications in the ﬁrst half of the experience,
decreasing to 5.8% in the second half, although this
was not statistically signiﬁcant.
Post-procedural medications varied. That is of
great importance in terms of assessing the results.
Conventionally, with the Watchman device, VKA is
administered following implantation for 45 days;
however, in this series, 24.5% of patients were not
eligible for anticoagulant agents. Accordingly, dual
antiplatelet therapy (DAPT) was administered for 6
months in 41.8%, whereas the remaining patients
(58.2%) received VKA for 45 days followed by DAPT
until 6-month follow-up.
Follow-up was available in 96 patients for a mean
of 3.1  1.6 years; the longest follow-up was out to
5 years. Assessment of the follow-up is of major
importance with this technology. Both echocardio-
graphic and clinical follow-up data were available.
A single patient had residual ﬂow around the device
because of an uncovered lobe at the time of
implantation; during follow-up, no other patient had
a signiﬁcant peri-device leak ($5 mm). Major clinical
events were infrequent: 2 patients had an ischemic
stroke occurring >12 months post-implantation,
whereas 2 additional patients had a transient
ischemic attack. Accordingly, the rate of transient
ischemic attack/stroke was 1.4% per year. Although no
control group was included, on the basis of the
CHADS2-VASc score, the annual stroke risk would
have been substantially greater. Using this score for
CHADS2-VASc patients with a score of 4, the predicted
annual stroke risk is 4%, whereas for those with a
CHADS2-VASc score of 5, the predicted annual risk
of stroke is 6.7%. Intracerebral hemorrhage occurred
in 3 patients: 1 patient on VKA and aspirin, 1 on aspirin
and clopidogrel, and 1 on aspirin alone. Accordingly,the combined rate of ischemia and intracerebral
hemorrhage was 2.5 per year. Severe bleeding
requiring hospitalization occurred in 6 patients with
an annual rate of 2.1%. Seven additional patients
died during follow-up; in 5 of these, mortality was
not related to stroke, atrial ﬁbrillation, or bleeding,
whereas in 2 patients, the cause was uncertain.
The investigators concluded that left atrial
appendage “closure with the Watchman device is safe
and feasible for stroke protection in patients with
atrial ﬁbrillation. Low ischemic event rates demon-
strated its effectiveness during long-term follow-up.”
(9). In addition to these conclusions, there are other
important pieces of information. A particularly
important one relates to the fact that despite the
current recommendation that all Watchman patients
be treated with VKA for 45 days, in this study only
58.2% received this treatment for 45 days, whereas in
41.8%, DAPT was administered instead for 6 months.
Despite that, although the numbers are very low,
event rates were not felt to be different between both
groups in regard to ischemic events, cerebral
bleeding, or thrombus on the left atrial appendage
occlusion device. However, again, the numbers of
patients with this are small. This, however, would be
consistent with the ASAP (ASA Plavix Feasibility
Study With Watchman Left Atrial Appendage Closure
Technology) trial of 150 patients who had a contra-
indication to anticoagulation (13).
This left atrial appendage occlusion technology
is transformational; closing the oval door offers the
potential for treatment of patients who have very
limited options for stroke prevention by virtue of
associated conditions or patient or physician prefer-
ence that limit the use of anticoagulant agents. As
such, it meets a substantial clinical need. There are
issues that continue to be evaluated in closing the
oval door. 1) What is the best device to close the door,
which is actually oval in most patients? This does
have important implications because the current de-
vices are circular, and when placed in an oval oriﬁce
may lead to persistent leaks; 2) What is the relative
role of this device in preventing ischemic versus
hemorrhagic stroke? It is obvious that local site-
speciﬁc therapy will not prevent stroke related to
noncardiac sources. However, in the published meta-
analysis (10), there is a dramatic reduction in hem-
orrhagic stroke, which is the most severe type of
stroke and is associated with the worst outcome; and
3) The observation that there is a substantial survival
advantage in patients treated with the device needs
to be conﬁrmed in larger studies. Such a dramatic
improvement in survival has major implications in
terms of patient and physician decision making.
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1924The story continues to develop. Closing the oval
door remains transformational with technology
documented to be, as the investigators conclude, safe
and feasible for stroke protection in patients with
atrial ﬁbrillation with low ischemic event rates during
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